Kineta. has filed a patent for compounds that can be used to treat or prevent neurological disorders. The compounds, either alone or in combination with other drugs, show potential for the treatment of neurological diseases. GlobalData’s report on Kineta gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kineta, Peptide pharmacophores was a key innovation area identified from patents. Kineta's grant share as of September 2023 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of neurological disorders
A recently filed patent (Publication Number: US20230271965A1) describes a compound of formula (I) and its various derivatives. The compound is claimed to have potential therapeutic applications in treating neurological disorders such as FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, and frontotemporal lobar degeneration.
The compound of formula (I) is described as having a single bond (claim 2) and X1 as (C(RA)2)m, where m is 1 (claim 4). Each RA in the compound is hydrogen (claim 6). The patent also includes several variations of the compound, such as formula (Ia), (Ia'), (Ib), (Ic), (Id), and (Ie) (claims 7-12).
The patent further claims that the compound can be used in pharmaceutical compositions (claim 29) and as a method of treating neurological disorders in subjects (claim 30). The neurological disorders mentioned include ALS, Alzheimer's disease, and FTLD-TDP (claims 31-32). The compound is also claimed to inhibit toxicity related to TDP-43 and C9orf72 proteins (claims 33-35) and inhibit PIKfyve in cells expressing PIKfyve protein (claim 36).
The methods described in the patent involve administering the compound or its pharmaceutically acceptable salt to the subject (claims 30, 40) and may include various substitutions and modifications in the compound structure (claims 41-60). The patent also mentions the use of the compound in treating TDP-43-associated disorders (claim 40).
Overall, the patent claims a compound of formula (I) and its derivatives as potential therapeutic agents for neurological disorders and provides methods for their use in treating these disorders and inhibiting toxicity in cells. However, it is important to note that the patent is still in the application stage and has not been granted yet.
To know more about GlobalData’s detailed insights on Kineta, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
